Target Name: DDX11L9
NCBI ID: G100288486
Review Report on DDX11L9 Target / Biomarker Content of Review Report on DDX11L9 Target / Biomarker
Other Name(s): DEAD/H-box helicase 11 like 9 (pseudogene), transcript variant 1 | DDX11L9 variant 1 | DEAD/H-box helicase 11 like 9 (pseudogene)

DDX11L9: A Potential Drug Target and Biomarker for ALS

Ammonium-conjugated[15N]-9-fluorenylmethyl-3-isothiocyanate (DDX11L9) is a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). ALS is a progressive neurodegenerative disease that affects approximately 400,000 people worldwide, primarily affecting people between the ages of 30 and 50. The symptoms of ALS include progressive muscle weakness and wasting, which can progress to the point of complete paralysis and loss of motor skills. Currently, there is no cure for ALS, and the disease is typically treated with supportive care and symptomatic relief.

The search for new treatments for ALS has led to the development of DDX11L9, a potential drug target and biomarker. In this article, we will explore the potential mechanisms of DDX11L9 and its potential as a treatment for ALS.

Mechanisms of DDX11L9

DDX11L9 is a small molecule that is derived from the amino acid leucine. It is capable of binding to the protein called Val65, which is a key regulator of the protein known as alpha-synuclein. alpha-synuclein is a protein that is found in the brain and is known to be a component of the neurodegenerate protein tau.

Research has shown that alpha-synuclein is abnormally expressed in the brains of people with ALS, and that it is involved in the development and progression of the disease. By binding to Val65, DDX11L9 is able to regulate the level of alpha-synuclein in the brain, which may have therapeutic benefits for ALS.

Potential Therapeutic Benefits of DDX11L9

The primary potential therapeutic benefit of DDX11L9 is its ability to regulate the level of alpha-synuclein in the brain. Alpha-synuclein is a protein that is known to contribute to the formation of beta-tubules, which are a structure that supports and transports neural signals in the brain. The formation of beta-tubules is disrupted in ALS, which is thought to contribute to the progressive neurodegeneration that occurs in the disease.

By regulating the level of alpha-synuclein in the brain, DDX11L9 may help to slow down the progression of ALS and potentially improve motor function in patients. This could be achieved through a variety of mechanisms, including:

* Reducing the formation of beta-tubules, which could potentially contribute to the progressive neurodegeneration that occurs in ALS.
* Promoting the clearance of beta-tubules, which could potentially help to reverse the formation of beta-tubules that occurs in ALS.
* Interfering with the function of beta-tubules, which could potentially disrupt the transport of neural signals in the brain and contribute to the progressive neurodegeneration that occurs in ALS.

Measurement of DDX11L9

In order to determine the potential therapeutic benefits of DDX11L9, it is important to measure its effectiveness. This can be done through a variety of tests, including in vitro assays, animal models of ALS, and clinical trials.

In vitro assays

In vitro assays can be used to measure the effects of DDX11L9 on the formation of beta-tubules in the brain. One possible method for doing this is to use cultured brain cells that have been genetically modified to express the alpha-synuclein protein. The cells can then be treated with DDX11L9, and the level of alpha-synuclein in the cells can be measured. This can provide information on the effectiveness of DDX11L9 in

Protein Name: DEAD/H-box Helicase 11 Like 9 (pseudogene)

The "DDX11L9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX11L9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

DDX12P | DDX17 | DDX18 | DDX18P1 | DDX19A | DDX19A-DT | DDX19B | DDX20 | DDX21 | DDX23 | DDX24 | DDX25 | DDX27 | DDX28 | DDX31 | DDX39A | DDX39B | DDX39B-AS1 | DDX3P1 | DDX3X | DDX3Y | DDX4 | DDX41 | DDX42 | DDX43 | DDX46 | DDX47 | DDX49 | DDX5 | DDX50 | DDX50P1 | DDX51 | DDX52 | DDX53 | DDX54 | DDX55 | DDX56 | DDX59 | DDX59-AS1 | DDX6 | DDX60 | DDX60L | DDX6P1 | DEAF1 | Death-associated protein kinase | Decapping Complex | DECR1 | DECR2 | DEDD | DEDD2 | Dedicator of cytokinesis protein | DEF6 | DEF8 | DEFA1 | DEFA10P | DEFA11P | DEFA1B | DEFA3 | DEFA4 | DEFA5 | DEFA6 | DEFA7P | DEFA8P | DEFA9P | DEFB1 | DEFB103A | DEFB103B | DEFB104A | DEFB104B | DEFB105A | DEFB105B | DEFB106A | DEFB106B | DEFB107A | DEFB108B | DEFB108F | DEFB109A | DEFB109B | DEFB109C | DEFB110 | DEFB112 | DEFB113 | DEFB114 | DEFB115 | DEFB116 | DEFB118 | DEFB119 | DEFB121 | DEFB122 | DEFB123 | DEFB124 | DEFB125 | DEFB126 | DEFB127 | DEFB128 | DEFB129 | DEFB130A | DEFB131A | DEFB131B | DEFB132